Evidence for age as a modifier of genetic associations for lipid levels

Logan Dumitrescu1, Kristin Brown-Gentry, Robert Goodloe

  • 1Center for Human Genetics Research, Vanderbilt University, Nashville, TN 37232, USA.

Insights

This study used genome-wide association studies in children to find new genetic variants affecting lipid levels. A key finding was an age-dependent link between the SGSM2 gene variant rs2429917 and LDL cholesterol.

Area of Science:

  • Genetics
  • Biochemistry
  • Pediatrics

Background:

  • Plasma lipid concentrations are crucial cardiovascular disease risk factors.
  • Genetic variants play a role in lipid metabolism, but many remain undiscovered.
  • Pediatric populations offer unique opportunities for identifying novel genetic associations.

Purpose of the Study:

  • To identify novel genetic variants influencing plasma lipid concentrations using a genome-wide association study (GWAS) in children.
  • To validate initial findings in independent pediatric and adult cohorts.
  • To investigate age-dependent genetic effects on lipid levels.

Main Methods:

  • Conducted a GWAS in 411 children from St. Jude Children's Research Hospital.
  • Replicated promising associations (p < 10(-5)) in 1040 youths and 3508 adults from NHANES III.
  • Tested for gene-age interactions in the NHANES III cohort.

Main Results:

  • Three genotype-phenotype associations replicated in NHANES III youths, and three in NHANES III adults; no single association was significant in both.
  • The most significant association in African descent youths was between LDL-C and intronic rs2429917 (p=0.009).
  • A significant age-dependent association (p=0.024) was found between SGSM2 rs2429917 and LDL-C in NHANES III participants.

Conclusions:

  • Children are valuable for discovering novel genetic variants related to complex traits like lipid levels.
  • Age-dependent genetic effects are important to consider in lipid association studies.
  • The SGSM2 rs2429917 variant shows an age-dependent association with LDL-C, highlighting its potential role in lipid regulation.

Related Concept Videos

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution01:00

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution

Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are not...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption01:22

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption

As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
Lipid-derived Compounds in the Human Body01:31

Lipid-derived Compounds in the Human Body

Fats and lipids are crucial components in the human body. Some lipid-derived compounds, such as fat-soluble vitamins, eicosanoids, lipoproteins, and glycolipids, also play unique roles to support various  biological processes .
Fat-soluble Vitamins
Fat-soluble vitamins, including vitamins A, D, E, and K, are required in minimal quantities, but their deficiencies can lead to severely abnormal physiological conditions. For example, vitamin A deficiency can cause night blindness, dry skin, delayed...